Accelerated atherosclerosis in systemic lupus erythematosus: Mechanisms and prevention approaches

International Journal of Clinical Rheumatology

Volumn 7, Issue 5, 2012, Pages 527-539

  Wilhelm, Ashley J ^a   Major, Amy S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; B cells; belimumab; HDL; regulatory B cells; regulatory T cells; rituximab; systemic lupus erythematosus; T cells

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BELIMUMAB; CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 17; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE; PEPTIDE L 4F; PRAVASTATIN; RETINOIC ACID; RITUXIMAB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH17 CELL; ULCERATIVE COLITIS;

EID: 84867565444     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.46     Document Type: Review

References (122)

1. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat. Rev. Immunol. 6(7), 508-519 (2006).
2. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 105(9), 1135-1143 (2002).
3. Robertson AKL, Hansson GK. T cells in atherogenesis: For better or for worse? Arterioscleros. Thromb. Vasc. Biol. 26(11), 2421-2432 (2006).
4. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat. Rev. Immunol. 8(10), 802-815 (2008).
5. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 201(1), 17-32 (2008).
6. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92(9), 3893-3897 (1995).
7. Kotzin BL. Systemic lupus erythematosus. Cell 85, 303-306 (1996).
8. Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: An update. Curr. Opin. Rheumatol. 17(5), 518-522 (2005).
9. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 123(8), 933-944 (2011).
10. Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58(1), 15-25 (2008).
11. Aprahamian T, Bonegio R, Rizzo J et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177(5), 3028 (2006).
12. Stanic AK, Stein CM, Morgan AC et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 103(18), 7018-7023 (2006).
13. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60(2), 221-225 (1976).
14. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am. J. Epidemiol. 145(5), 408-415 (1997).
15. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13(5), 345-351 (2001).
16. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44(10), 2331-2337 (2001).
17. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42(1), 51-60 (1999).
18. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis Rheum. 61(10), 1396-1402 (2009).
19. Nossent J, Cikes N, Kiss E et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus 16(5), 309-317 (2007).
20. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54(8), 2550-2557 (2006).
21. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135(1), 169-175 (1989).
22. Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of ApoE-/- and LDL receptor-/- mice: Decreasing density with disease progression. Arterioscleros. Thromb. Vasc. Biol. 16(8), 1013-1018 (1996).
23. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arterioscleros. Thromb. Vasc. Biol. 6(2), 131-138 (1986).
24. Frostegård J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145(1), 33-43 (1999).
25. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102(24), 2919-2922 (2000).
26. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-g on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscleros. Thromb. Vasc. Biol. 23(3), 454-460 (2003).
27. Zhou X, Robertson AKL, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ. Res. 96(4), 427-434 (2005).
28. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am. J. Pathol. 172(6), 1500-1508 (2008).
29. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J. Immunol. 138(10), 3247-3253 (1987).
30. Mihara M, Ohsugi Y, Saito K et al. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. J. Immunol. 141(1), 85-90 (1988).
31. Dawisha SM, Gmelig-Meyling F, Steinberg AD. Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthritis Rheum. 37(2), 270-277 (1994).
32. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183(5), 3160-3169 (2009).
33. Budagyan VM, Bulanova EG, Sharova NI, Nikonova MF, Stanislav ML, Yarylin AA. The resistance of activated T-cells from SLE patients to apoptosis induced by human thymic stromal cells. Immunol. Lett. 60(1), 1-5 (1998).
34. Zhou Y, Yuan J, Pan Y et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin. Immunol. 132(3), 362-370 (2009).
35. Braun NA, Wade NS, Wakeland EK, Major AS. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr-/- mice. Lupus 17(12), 1070-1078 (2008).
36. André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: Immunopathogenesis and therapeutic implications. Am. J. Pathol. 174(5), 1575-1587 (2009).
37. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res. S364-S369 (2009).
38. Grainger DJ, Mosedale DE, Metcalfe JC, Böttinger EP. Dietary fat and reduced levels of TGFb1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J. Cell. Sci. 113, 2355-2361 (2000).
39. Mallat Z, Gojova A, Marchiol-Fournigault C et al. Inhibition of transforming growth factor-b signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89(10), 930-934 (2001).
40. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001).
41. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. (Internet) 39(8), 537-545 (2002).
42. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 177(3), 1451-1459 (2006).
43. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117(2), 280-286 (2006).
44. Venigalla RKC, Tretter T, Krienke S et al. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58(7), 2120-2130 (2008).
45. Divekar AA, Dubey S, Gangalum PR, Singh RR. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: An apparent paradox in the setting of an inflammatory milieu. J. Immunol. 186(2), 924-930 (2011).
46. Monk CR, Spachidou M, Rovis F et al. MRL/Mp CD4+, CD25- T cells show reduced sensitivity to suppression by CD4+, CD25+ regulatory T cells in vitro: A novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum. 52(4), 1180-1184 (2005).
47. Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology (Oxford) 47(6), 789-794 (2008).
48. Taleb S, Romain M, Ramkhelawon B et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206(10), 2067-2077 (2009).
49. Eid RE, Rao DA, Zhou J et al. Interleukin-17 and interferon-g are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119(10), 1424-1432 (2009).
50. Smith E, Prasad KMR, Butcher M et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121(15), 1746-1755 (2010).
51. Gao Q, Jiang Y, Ma T et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J. Immunol. 185, 5820-5827 (2010).
52. Xing Q, Wang B, Su H, Cui J, Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol. Int. 32(4), 949-958 (2012).
53. Hsu HC, Yang P, Wang J et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9(2), 166-175 (2008).
54. Chen XQ, Yu YC, Deng HH et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J. Clin. Immunol. 30(2), 221-225 (2010).
55. Shah K, Lee WW, Lee SH et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res. Ther. 12(2), R53 (2010).
56. Ma J, Yu J, Tao X, Cai L, Wang J, Zheng SG. The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. Clin. Rheumatol. 29(11), 1251-1258 (2010).
57. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109(6), 721-724 (2002).
58. Major AS, Fazio S, Linton MF. B-Lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscleros. Thromb. Vasc. Biol. 22(11), 1892-1898 (2002).
59. Ait-Oufella H, Herbin O, Bouaziz JD et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 207(8), 1579-1587 (2010).
60. Kyaw T, Tay C, Khan A et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J. Immunol. 185, 4410-4419 (2010).
61. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J. Immunol. 155, 3734-3741 (1995).
62. Gray D, Gray M, Barr T. Innate responses of B cells. Eur. J. Immunol. 37(12), 3304-3310 (2007).
63. Lund FE, Randall TD. Effector and regulatory B cells: Modulators of CD4+ T cell immunity. Nat. Rev. Immunol. 10(4), 236-247 (2010).
64. Sanz I, Lee FEH. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6(6), 326-337 (2010).
65. Blair PA, Chavez-Rueda KA, Evans JG et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr Mice. J. Immunol. 182, 3493-3502 (2009).
66. Teichmann LL, Kashgarian M, Weaver CT, Roers A, Müller W, Shlomchik MJ. B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL. Faslpr mice. J. Immunol. 188(2), 678-685 (2011).
67. Ray A, Basu S, Williams CB, Nita H, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J. Immunol. 188(7), 3188-3198 (2012).
68. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. NY Acad. Sci. 1183, 38-57 (2010).
69. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118(10), 3420-3430 (2008).
70. Blair PA, Noreña LY, Flores-Borja F et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32(1), 129-140 (2010).
71. Evans JG, Chavez-Rueda KA, Eddaoudi A et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178(12), 7868-7878 (2007).
72. McLaren JE, Ramji DP. Interferon g: A master regulator of atherosclerosis. Cytokine Growth Factor Rev. 20(2), 125-135 (2009).
73. Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. The role of IFN-g in systemic lupus erythematosus: A challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3(3), 136-141 (2001).
74. Postal M, Sinicato NA, Peliçari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-A levels in childhood-onset systemic lupus erythematosus. Clinics (São Paulo) 67(2), 157-162 (2012).
75. Ko K, Franek BS, Marion M et al. Genetic ancestry, serum interferon-A activity, and autoantibodies in systemic lupus erythematosus. J. Rheumatol. 39(6), 1238-1240 (2012).
76. Kaplan MJ, Salmon JE. How does interferon-A insult the vasculature? Let me count the ways. Arthritis Rheum. 63(2), 334-336 (2011).
77. Denny MF, Thacker S, Mehta H et al. Interferon-A promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood 110(8), 2907-2915 (2007).
78. Li J, Fu Q, Cui H et al. Interferon-A priming promotes lipid uptake and macrophage-derived foam cell formation: A novel link between interferon-A and atherosclerosis in lupus. Arthritis Rheum. 63(2), 492-502 (2011).
79. Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc. Med. J. 5, 64-75 (2011).
80. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62(5), 707-714 (1977).
81. Hyka N. Apolipoprotein A-I inhibits the production of interleukin-1b and tumor necrosis factor-A by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97(8), 2381-2389 (2001).
82. Wilhelm AJ, Zabalawi M, Grayson JM et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscleros. Thromb. Vasc. Biol. 29(6), 843-849 (2009).
83. McMahon M, Grossman J, Skaggs B et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 60(8), 2428-2437 (2009).
84. Ames PRJ, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: Preliminary data. Ann. Rheum. Dis. 64(2), 315-317 (2005).
85. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50 year-old men predict myocardial infarction. Arterioscleros. Thromb. Vasc. Biol. 17(11), 3159-3163 (1997).
86. Vaarala O, Manttari M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91(1), 23-27 (1995).
87. Toloza SMA, Uribe AG, McGwin G et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 50(12), 3947-3957 (2004).
88. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349(25), 2399-2406 (2003).
89. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 12(3), 204-212 (2011).
90. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222-233 (2010).
91. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 64(4), 1215-1226 (2012).
92. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 57(5), 714-715 (2008).
93. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56(8), 2715-2718 (2007).
94. Stohl W, Hiepe F, Latinis KM et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64(7), 2328-2337 (2012).
95. Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat. Biotechnol. 30(1), 69-77 (2012).
96. Kyaw T, Tay C, Hosseini H et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE-/- mice attenuates atherosclerosis by potently ameliorating arterial inflammation. Atherosclerosis 7(1), 1-10 (2012).
97. Sage AP, Tsiantoulas D, Baker L et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice. Arterioscleros. Thromb. Vasc. Biol. 32(7), 1573-1576 (2012).
98. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, E17-E24 (1999).
99. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 24(8), 2869-2880 (2010).
100. Yin Z, Bahtiyar G, Zhang N et al. IL-10 regulates murine lupus. J. Immunol. 169(4), 2148-2155 (2002).
101. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179(1), 305-310 (1994).
102. Lu L, Ma J, Li Z et al. All-trans retinoic acid promotes TGF-b-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus. PLoS One 6(9), E24590 (2011).
103. Xiao S, Jin H, Korn T et al. Retinoic acid increases Foxp3 regulatory T cells and inhibits development of Th17 cells by enhancing TGF-b-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 181, 2277-2284 (2008).
104. Sobel ES, Brusko TM, Butfiloski EJ et al. Defective response of CD4+ T cells to retinoic acid and TGFb in systemic lupus erythematosus. Arthritis Res. Ther. 13(3), R106 (2011).
105. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 14(3), S2-S8 (2005).
106. Zhao L, Jiang Z, Jiang Y, Ma N, Wang K, Zhang Y. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. Clin. Rheumatol. 31(6), 951-959 (2012).
107. van Leuven SI, van Wijk DF, Volger OL et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211(1), 231-236 (2010).
108. van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr-/- mice. Ann. Rheum. Dis. 71(3), 408-414 (2012).
109. Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol. Int. 32(9), 2701-2705 (2011).
110. Woo JMP, Lin Z, Navab M et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res. Ther. 12(3), R93 (2010).
111. Van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS. Statin therapy in lupus-mediated atherogenesis: Two birds with one stone? Ann. Rheum. Dis. 70(2), 245-248 (2011).
112. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 weeks controlled trial. Rheumatology 46(10), 1560-1565 (2007).
113. Petri MA, Kiani AN, Post W, Christopher- Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann. Rheum. Dis. 70(5), 760-765 (2011).
114. Schanberg LE, Sandborg C, Barnhart HX et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 64(1), 285-296 (2012).
115. Fessler BJ, Alarcón GS, McGwin G et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52(5), 1473-1480 (2005).
116. Willis R, Seif A, McGwin G et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21(8), 830-835 (2012).
117. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: Effects of lipids, glucose and thrombosis. Lupus 1(Suppl.), S16-S22 (1996).
118. Wallace D, Metzger A, Stecher V, Turnbull B, Kern P. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am. J. Med. 89, 322-326 (1990).
119. Rahman P, Gladman D, Urowitz MB, Yuen K, Hallett D, Bruce I. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol. 26, 325-330 (1999).
120. Cairoli E, Rebella M, Danese N, Garra V, Borba E. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: A longitudinal evaluation of the lipid-lowering effect. Lupus 21(11), 1178-1182 (2012).
121. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37(4), 1075-1082 (2001).
122. Wilhelm AJ, Zabalawi M, Owen JS et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J. Biol. Chem. 285(46), 36158-36169 (2010).